HLB PANAGENE Co., LTD. Logo

HLB PANAGENE Co., LTD.

A global leader in PNA technology for cancer diagnostics and precision medicine.

046210 | KO

Overview

Corporate Details

ISIN(s):
KR7046210001
LEI:
Country:
South Korea
Address:
대전광역시 유성구 테크노10로 54, 대전광역시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

HLB PANAGENE Co., LTD. is a global molecular diagnostics company specializing in the development and commercialization of products based on its proprietary Peptide Nucleic Acid (PNA) technology. As a leading worldwide supplier of PNA materials, the company provides innovative solutions for in-vitro diagnostics (IVD), companion diagnostics (CDx), and liquid biopsy, primarily targeting oncology and precision medicine. Its portfolio includes diagnostic kits for detecting cancer-related mutations, such as the PANA Mutyper™ series for lung cancer. The company is actively expanding its global market presence and is integrating Artificial Intelligence (AI) to develop a next-generation multimodal diagnostic platform, aiming to advance personalized healthcare and cancer diagnostics. Formerly known as Panagene Inc., the company changed its name in 2023.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-26 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 121.6 KB
2025-08-26 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-08-26 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 101.6 KB
2025-08-20 00:00
Capital/Financing Update
주권관련사채권의취득결정
Korean 38.2 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.3 MB
2025-07-18 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.8 MB
2025-07-18 00:00
Capital/Financing Update
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 15.2 KB
2025-07-18 00:00
Capital/Financing Update
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 14.3 KB
2025-06-05 00:00
Share Issue/Capital Change
전환청구권행사
Korean 11.3 KB
2025-05-19 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 230.1 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.3 MB
2025-05-14 00:00
Share Issue/Capital Change
전환청구권행사
Korean 11.3 KB
2025-04-22 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-04-22 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 100.3 KB
2025-04-18 00:00
Capital/Financing Update
전환가액의조정
Korean 16.4 KB

Automate Your Workflow. Get a real-time feed of all HLB PANAGENE Co., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for HLB PANAGENE Co., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for HLB PANAGENE Co., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

AIM ImmunoTech Inc. Logo
Develops immuno-therapeutics for cancers, immune disorders, and viral diseases.
United States of America
AIM
AKANDA CORP. Logo
Cultivates and distributes pharma-quality medical cannabis for patients in legal markets worldwide.
United States of America
AKAN
Akari Therapeutics Plc Logo
A clinical-stage oncology company developing next-gen ADCs for targeted cancer therapy.
United States of America
AKTX
Akebia Therapeutics, Inc. Logo
Developing and commercializing novel, FDA-approved therapeutics for kidney disease.
United States of America
AKBA
Akero Therapeutics, Inc. Logo
A clinical-stage biotech developing therapies for serious metabolic diseases like MASH.
United States of America
AKRO
Alaunos Therapeutics, Inc. Logo
Developing TCR-T cell therapies to treat solid tumors by targeting specific cancer mutations.
United States of America
TCRT
Aldeyra Therapeutics, Inc. Logo
Biotech developing therapies for ocular and systemic immune-mediated inflammation.
United States of America
ALDX
Alector, Inc. Logo
Pioneers immuno-neurology therapies for neurodegenerative diseases like Alzheimer's.
United States of America
ALEC
Aligos Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel oral therapies for liver and viral diseases.
United States of America
ALGS
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark
ALK

Talk to a Data Expert

Have a question? We'll get back to you promptly.